Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus patients
Current evidence supports risk-adapted primary prophylaxis and individualized secondary prophylaxis for as long as clinically meaningful immunosuppression persists, complemented by infection-control measures in units caring for highly immunocompromised patients.